GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicycle Therapeutics PLC (NAS:BCYC) » Definitions » Degree of Operating Leverage

BCYC (Bicycle Therapeutics) Degree of Operating Leverage : -0.72 (As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Bicycle Therapeutics Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Bicycle Therapeutics's Degree of Operating Leverage for the quarter that ended in Mar. 2025 was -0.72. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for Bicycle Therapeutics's Degree of Operating Leverage or its related term are showing as below:

BCYC's Degree of Operating Leverage is ranked better than
68.74% of 886 companies
in the Biotechnology industry
Industry Median: -0.02 vs BCYC: -0.72

Bicycle Therapeutics Degree of Operating Leverage Historical Data

The historical data trend for Bicycle Therapeutics's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bicycle Therapeutics Degree of Operating Leverage Chart

Bicycle Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial -2.77 2.20 2.93 0.68 -0.07

Bicycle Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.20 0.13 -0.07 -0.72

Competitive Comparison of Bicycle Therapeutics's Degree of Operating Leverage

For the Biotechnology subindustry, Bicycle Therapeutics's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bicycle Therapeutics's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicycle Therapeutics's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Bicycle Therapeutics's Degree of Operating Leverage falls into.


;
;

Bicycle Therapeutics Degree of Operating Leverage Calculation

Bicycle Therapeutics's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -207.764 (Mar. 2025) / -163.162 (Mar. 2024) - 1 )/( 25.722 (Mar. 2025) / 41.61 (Mar. 2024) - 1 )
=0.2734/-0.3818
=-0.72***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Bicycle Therapeutics  (NAS:BCYC) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Bicycle Therapeutics Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Bicycle Therapeutics's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Bicycle Therapeutics Business Description

Traded in Other Exchanges
Address
Granta Park, Great Abington, Blocks A and B, Portway Building, Cambridge, GBR, CB21 6GS
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
Executives
Travis Alvin Thompson officer: Chief Accounting Officer C/O BICYCLE THERAPEUTICS PLC, BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE X0 CB21 6GS
Alistair Milnes officer: Chief Operating Officer C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Kevin Lee director, officer: Chief Executive Officer C/O BICYCLE THERAPEUTICS LIMITED, B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB223AT
Michael Skynner officer: Chief Operating Officer C/O BICYCLE THERAPEUTICS LIMITED, B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB223AT
Alethia Young officer: Chief Financial Officer C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Nigel Crockett officer: Chief Business Officer C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Santiago Arroyo officer: Chief Development Officer C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Nicholas Keen officer: Chief Scientific Officer C/O BICYCLE THEAPEUTICS LIMITED, B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Lee Kalowski officer: President and CFO C/O TOKAI PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Dominic Smethurst officer: Chief Medical Officer C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Pierre Legault director P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Kate Bingham director 1365 MAIN STREET, WALTHAM MA 02451
Jose-carlos Gutierrez-ramos director C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Plc Glaxosmithkline director, 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Veronica Gh Jordan director C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098